Monsanto Company (NYSE: MON) and TargetGene Biotechnologies LTD, a pioneer in genome-editing technologies, have announced a license agreement to advance the application of the company’s proprietary techniques in global agriculture. TargetGene is an innovative genome-editing company using RNA-guided gene-editing techniques.

Under the agreement, Monsanto has been granted an exclusive license to TargetGene’s novel and proprietary "T∙GEE" (Genome Editing Engine) platform to deliver continuous improvements in agriculture. Monsanto has also established an equity position in the private Israel-based company. Additional terms of the agreement were not disclosed.

“TargetGene is pleased to be working with Monsanto to enable the next generation of agricultural innovation through the application of our genome-editing technology,” said Dr. Yoel Shiboleth, chief executive officer of TargetGene. “In a time of increasing environmental challenges and a growing global population to feed, this science has never been more important.”

“TargetGene has uniquely positioned itself to develop precision-editing techniques that can improve a broad range of solutions that help growers around the world deliver better harvests,” said Tom Adams, biotechnology lead for Monsanto. “Monsanto has conducted extensive research with various gene-editing approaches for years, and we believe access to TargetGene’s technology will help drive further precision and efficiency within the company’s robust plant breeding and biotechnology pipelines.”

The companies noted that gene-editing technology and the broad array of emerging gene-editing techniques represent a key scientific tool that can deliver breakthroughs in agriculture. The science is the biological equivalent to the “search and replace” function in computer word-processors. Monsanto believes that genome-editing technologies will enable plant breeders to deliver better hybrids and varieties more efficiently, as well as offer plant scientists additional resources to provide new improvements in plant biotechnology.

About TargetGene Biotechnologies LTD

TargetGene Biotechnologies is a privately held company developing a proprietary ground breaking Genome Editing technology, based on the founders’ invention of the principle of RNA-directed gene-targeting. The company, incorporated 2012, is located in the Rehovot Science Park, one of Israel’s leading biotechnology clusters. TargetGene’s R&D is aimed at creating precise and highly specific DNA editing solutions in living organisms for agricultural, veterinary and therapeutic use.

About Monsanto Company

Monsanto is committed to bringing a broad range of solutions to help nourish our growing world. We produce seeds for fruits, vegetables and key crops – such as corn, soybeans, and cotton – that help farmers have better harvests while using water and other important resources more efficiently. We work to find sustainable solutions for soil health, help farmers use data to improve farming practices and conserve natural resources, and provide crop protection products to minimize damage from pests and disease. Through programs and partnerships, we collaborate with farmers, researchers, nonprofit organizations, universities and others to help tackle some of the world’s biggest challenges. To learn more about Monsanto, our commitments and our more than 20,000 dedicated employees, please visit: discover.monsanto.com and monsanto.com. Follow our business on Twitter® at twitter.com/MonsantoCo, on the company blog, Beyond the Rows® at monsantoblog.com or subscribe to our News Release RSS Feed.